

## RESEARCH ARTICLE

# Genetic modifiers of respiratory function in Duchenne muscular dystrophy

Luca Bello<sup>1</sup> , Grazia D'Angelo<sup>2</sup>, Matteo Villa<sup>1</sup>, Aurora Fusto<sup>1</sup>, Sara Vianello<sup>1</sup>, Beatrice Merlo<sup>1</sup>, Daniele Sabbatini<sup>1</sup>, Andrea Barp<sup>1</sup>, Sandra Gandossini<sup>2</sup>, Francesca Magri<sup>3,4</sup>, Giacomo P. Comi<sup>3,4</sup> , Marina Pedemonte<sup>5</sup>, Paola Tacchetti<sup>5</sup>, Valentina Lanzillotta<sup>5</sup>, Federica Trucco<sup>5</sup>, Adele D'Amico<sup>6</sup>, Enrico Bertini<sup>6</sup>, Guja Astrea<sup>7</sup>, Luisa Politano<sup>8</sup>, Riccardo Masson<sup>9</sup>, Giovanni Baranello<sup>9,10</sup>, Emilio Albamonte<sup>11</sup>, Elisa De Mattia<sup>11</sup>, Fabrizio Rao<sup>11</sup>, Valeria A. Sansone<sup>11</sup>, Stefano Previtali<sup>12</sup> , Sonia Messina<sup>13</sup>, Gian Luca Vita<sup>13</sup>, Angela Berardinelli<sup>14</sup>, Tiziana Mongini<sup>15</sup>, Antonella Pini<sup>16</sup>, Marika Pane<sup>17,18</sup>, Eugenio Mercuri<sup>17,18</sup> , Andrea Vianello<sup>19</sup>, Claudio Bruno<sup>5</sup>, Eric P. Hoffman<sup>20,21</sup>, Lauren Morgenroth<sup>21</sup>, Heather Gordish-Dressman<sup>21</sup>, Craig M. McDonald<sup>22</sup>, CINRG-DNHS Investigators & Elena Pegoraro<sup>1</sup> 

<sup>1</sup>Department of Neurosciences DNS, University of Padova, Padova, Italy

<sup>2</sup>NeuroMuscular Unit, Scientific Institute IRCCS E. Medea, Bosisio Parini (Lecco), Italy

<sup>3</sup>IRCCS Foundation, Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

<sup>4</sup>Dino Ferrari Centre, Department of Pathophysiology and Transplantation (DEPT), University of Milan, Milan, Italy

<sup>5</sup>Center of Translational and Experimental Myology, IRCCS Istituto Giannina Gaslini, Genova, Italy

<sup>6</sup>Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children's Hospital IRCCS, Rome, Italy

<sup>7</sup>Department of Developmental Neuroscience, IRCCS Stella Maris, Calambrone, Pisa, Italy

<sup>8</sup>Cardiomyology and Medical Genetics, Department of Experimental Medicine, "Vanvitelli" University of Campania, Naples, Italy

<sup>9</sup>Developmental Neurology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

<sup>10</sup>The Dubowitz Neuromuscular Centre, NIHR BRC University College London Great Ormond Street Institute of Child Health & Great Ormond Street Hospital, London, United Kingdom

<sup>11</sup>Neurorehabilitation Unit, Centro Clinico NeMO, University of Milan, Milan, Italy

<sup>12</sup>Neuromuscular Repair Unit, Inspe and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy

<sup>13</sup>Department of Neurosciences and Nemo Sud Clinical Center, University of Messina, Messina, Italy

<sup>14</sup>"C. Mondino" Foundation, Pavia, Italy

<sup>15</sup>Neuromuscular Center, AOU Città della Salute e della Scienza, University of Torino, Turin, Italy

<sup>16</sup>Child Neurology and Psychiatry Unit, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy

<sup>17</sup>Pediatric Neurology, Department of Woman and Child Health and Public Health, Child Health Area, Università Cattolica del Sacro Cuore, Rome, Italy

<sup>18</sup>Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

<sup>19</sup>Department of Cardio-Thoracic Sciences, Respiratory Pathophysiology Division, University-City Hospital of Padova, Padova, Italy

<sup>20</sup>Binghamton University - SUNY, Binghamton, New York

<sup>21</sup>Center for Genetic Medicine, Children's Research Institute, Children's National Health System, Washington, District of Columbia

<sup>22</sup>University of California Davis Medical Center, Sacramento, California

[Corrections added on 14 May 2020 after first publication: The 5th affiliation has been corrected.]

## Correspondence

Elena Pegoraro, Department of Neurosciences, University of Padova, via Giustiniani, 5, 35128 Padova, Italy. Tel: +39 049 821 3622; Fax: +309 049 875 1770; E-mail: elena.pegoraro@unipd.it

## Funding Information

We acknowledge funding from Santhera Pharmaceuticals, which supported the collection and analyses of data from the Italian cohort. EP also acknowledges funding from the Cariparo Foundation (Progetto di Eccellenza "GenMod" 2017), and from

## Abstract

**Objective:** Respiratory insufficiency is a major complication of Duchenne muscular dystrophy (DMD). Its progression shows considerable interindividual variability, which has been less thoroughly characterized and understood than in skeletal muscle. We collected pulmonary function testing (PFT) data from a large retrospective cohort followed at Centers collaborating in the Italian DMD Network. Furthermore, we analyzed PFT associations with different *DMD* mutation types, and with genetic variants in *SPPI*, *LTBP4*, *CD40*, and *ACTN3*, known to modify skeletal muscle weakness in DMD. Genetic association findings were independently validated in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study (CINRG-DNHS). **Methods and Results:** Generalized estimating equation analysis of 1852 PFTs from 327 Italian DMD patients, over an average follow-up time of 4.5 years,

Telethon Genetic BioBank (GTB12001D) and the Eurobiobank Network. The CINRG-DNHS was funded by the U.S. Department of Education/NIDRR (#H133B031118, #H133B090001); U.S. Department of Defense (#W81XWH-12-1-0417); National Institutes of Health/NIAMS (#R01AR061875); Parent Project Muscular Dystrophy.

Received: 23 February 2020; Revised: 18 March 2020; Accepted: 26 March 2020

**Annals of Clinical and Translational Neurology 2020; 7(5): 786–798**

doi: 10.1002/acn3.51046

## Introduction

Duchenne muscular dystrophy (DMD) is caused by *DMD* mutations leading to complete or near-complete dystrophin defects in skeletal muscle,<sup>1</sup> resulting in its fibrofatty degeneration.<sup>2</sup> Skeletal muscle weakness is the most distinctive clinical feature; however, respiratory muscle weakness impacts life quality and expectancy even more heavily.<sup>3</sup> Inspiratory/expiratory dysfunction appears around the age of 10, and progresses over the years,<sup>4,5</sup> eventually leading to nocturnal ventilatory insufficiency requiring noninvasive ventilatory assistance (NIV), reduced airway clearance, and infections. Eventually, daytime or continuous NIV becomes necessary, and sometimes tracheostomy.<sup>3</sup>

As novel treatments emerge for DMD, a quantitative description of its respiratory “natural history” is paramount for the design and interpretation of trials including respiratory endpoints. Current standards of care recommend pulmonary function tests (PFTs) yearly in ambulatory patients, and twice yearly in nonambulatory, as forced vital capacity (FVC) below 1 L or below 50% of the predicted value by age and height<sup>6</sup> indicates a risk of nocturnal hypoventilation. It has been shown in different DMD cohorts that percent-predicted FVC and peak expiratory flow (PEF) decrease gradually and colinearly, especially during intermediate disease stages (i.e. approximately before 10 or after the 20 years of age; or above 80% and below 30% of predicted FVC values).<sup>4,5,7</sup>

As seen for skeletal muscle, a striking interindividual variability is observed in PFT deterioration.<sup>7</sup> Other than glucocorticoid (GC) treatment and standards of care,<sup>6,8,9</sup> several genetic factors have been called into play as modifiers of DMD severity. These include “cis-acting” modifiers, such as specific *DMD* mutations which may lead to the expression of minimal, but clinically relevant quantities of dystrophin<sup>10–13</sup>; and “trans-acting” modifiers, that is,

estimated that forced vital capacity (FVC) declined yearly by  $-4.2\%$ , forced expiratory volume in 1 sec by  $-5.0\%$ , and peak expiratory flow (PEF) by  $-2.9\%$ . Glucocorticoid (GC) treatment was associated with higher values of all PFT measures (approximately  $+15\%$  across disease stages). Mutations situated 3' of *DMD* intron 44, thus predicted to alter the expression of short dystrophin isoforms, were associated with lower (approximately  $-6\%$ ) PFT values, a finding independently validated in the CINRG-DNHS. Deletions amenable to skipping of exon 51 and 53 were independently associated with worse PFT outcomes. A meta-analysis of the two cohorts identified detrimental effects of *SPP1* rs28357094 and *CD40* rs1883832 minor alleles on both FVC and PEF. **Interpretation:** These findings support GC efficacy in delaying respiratory insufficiency, and will be useful for the design and interpretation of clinical trials focused on respiratory endpoints in DMD.

polymorphisms in genes different from *DMD*, that may influence the pathological consequences of dystrophin deficiency.<sup>14–17</sup> As specific *DMD* mutations are now amenable to targeted molecular treatments,<sup>18</sup> such as “exon skipping” antisense oligonucleotides, or small molecules promoting stop codon readthrough, delineating “natural history” trajectories in corresponding subgroups are useful.

Here we aimed at describing the natural history of, and effect of GC treatment on respiratory insufficiency, in a large retrospective cohort followed by the Italian DMD Network. Furthermore, we analyzed the respiratory effects of several genetic variables, previously associated with differential DMD expressivity. As replication of genetic association findings in independent cohorts is crucial,<sup>19</sup> we validated findings in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study (CINRG-DNHS) cohort.

## Methods

### Cohorts

Collaborating Italian Centers collected retrospective PFT data from clinical records of patients followed from January 1990 to May 2018 (henceforth: “Italian cohort”), with the aim of describing respiratory natural history and GC effects. These have been described elsewhere for the CINRG-DNHS cohort,<sup>6</sup> which was used here to validate genetic associations.

### Ethics statement

All participants or their parents/guardians provided informed consent to study procedures, which were carried out in accordance with the Declaration of Helsinki and approved by Ethics Committees/Institutional Review Boards in the participating Institutions.

## Inclusion criteria

We selected Italian cohort patients with frameshifting or nonsense *DMD* mutations; or absent or <3% dystrophin detected by immunohistochemistry (except revertant fibers) or immunoblot; or any *DMD* mutation, plus absent dystrophin as above and/or overt muscle weakness by 5 years, or loss of independent ambulation (LoA) by 13 years without GC treatment, or 16 with GCs. CINRG-DNHS criteria were similar.<sup>20</sup>

## PFTs

PFTs were performed according to international guidelines,<sup>21</sup> and available measurements of FVC, FEV1 (forced expiratory volume in 1 sec), and PEF, expressed as % of predicted, were collected retrospectively. Age and GC treatment status at the time of PFTs, and age at commencement of NIV were collected when available. PFTs in the CINRG-DNHS were performed longitudinally as described.<sup>4</sup>

## DMD genotype

Information about pathogenic *DMD* mutations was collected when available from clinical records or genetic reports. We classified deletions based on amenability to molecular treatments, that is, skipping of exons 8, 44, 45, 51, and 53 (henceforth: “skip 8”, “skip 44”, etc.). Nonsense and splice mutations were also considered as separate groups. Moreover, mutations were subdivided into “proximal”, that is, situated 5' of intron 44, and therefore not predicted to alter the expression of short dystrophin isoforms (Dp140, Dp116, and Dp71); and “distal”, that is, involving intron 44 and/or regions 3' of it, thus disrupting these isoforms. The same criteria were adopted to classify CINRG-DNHS participants with available *DMD* mutation data, as described.<sup>10</sup>

## Modifier genotypes

Patients with available DNA samples were genotyped by TaqMan probes at the main known *DMD* modifier loci: *SPP1* rs28357094,<sup>14</sup> *LTBP4* rs10880,<sup>15</sup> *CD40* rs1883832,<sup>16</sup> and *ACTN3* rs1815739.<sup>17</sup> For tests of genotype/phenotype association, we used the same inheritance models as in published reports.

## Test/validation and “meta-analysis”

For genotype/phenotype associations, we used both a test/validation approach, that is, same statistical tests in the Italian and CINRG-DNHS cohorts; and a “meta-analysis” approach, that is, same tests in the merged Italian and

CINRG datasets (including all individual data points). This is justified by the consideration that there is no existing estimate of mutation/SNP effect sizes on the respiratory phenotype, so that formal power calculations are not feasible, leaving the possibility that the test and/or validation cohorts alone may be undersized to identify relevant effects.

## Statistical analysis

Quantitative variables were summarized as mean  $\pm$  standard deviation and median (range), unless otherwise specified. Intervals of linear decline of PFT measures were defined by piecewise regression, using baseline data and choosing a two-break model for FVC/FEV1, and a one-break model for PEF after visual inspection of the data. Generalized Estimating Equations (GEEs), a regression model adequate for clustered longitudinal data were used to estimate effects of several covariates: age; GC treatment (on vs. off at each PFT); *DMD* mutation (tested separately: each specified mutation group vs. “other” mutations; or “distal” vs. “proximal”); and SNP genotypes (dominant, recessive, or additive as appropriate). GEEs were applied within the “linear” age range defined by piecewise regression, using the same range for test/validation, and recalculating it for meta-analysis. NIV commencement was studied with time-to-event analyses, using age as the time variable. NIV-free participants were censored. Median age at NIV was estimated with the Kaplan–Meier method. Statistical significance was set at  $P < 0.01$  (Bonferroni correction for five loci: *DMD*, *SPP1*, *LTBP4*, *CD40*, *ACTN3*). No Bonferroni correction was applied to multiple PFT outcomes as these are strongly intercorrelated and reflect inspiratory/expiratory strength. Statistical analyses were performed using R v.3.5.2.

## Results

### Demographics

For the Italian cohort, we collected data from 1852 PFT evaluations performed by 327 *DMD* patients, mean age:  $11.7 \pm 5.3$  years, from 1990 to 2018. On average, participants underwent  $5.7 \pm 4.5$  evaluations (maximum 19), performed every  $0.97 \pm 0.88$  years, with a follow-up time of  $4.5 \pm 3.9$  years (maximum 19.4). At last evaluation, average age was  $16.3 \pm 6.6$  years. Features of the CINRG-DNHS cohort have been described.<sup>4</sup> All patients were male.

### GC treatment

During follow-up, 134 patients (41.0%) were continuously on GC treatment, while 116 (35.5%) were

continuously off. Untreated patients were older than those treated (approximately 5-year difference). GC treatment in the CINRG-DNHS cohort has been described (Table 1).<sup>4</sup>

### DMD mutations

DMD mutations were defined in 274 (83.8%) patients in the Italian cohort. As expected, single- or multiexon deletions represented the majority of mutations (70.1%), followed by duplications (11.3%) and nonsense mutations (9.5%). The mutations were “distal” (3' of exon 44) in 168/274 participants (61.3%), and “proximal” (5' of intron 44) in 103/274 (37.6%). Three mutations (1.1%) were reported as “nonsense” or “splice site”, but no nucleotide position was available, so that “distal” versus “proximal” could not be determined. Distribution by mutations in the CINRG-DNHS was similar, as described previously,<sup>10</sup> with 66.9% “distal” and 33.1% “proximal” mutations. The CINRG-DNHS subpopulation with available mutational and PFT data ( $n = 175$ ) is also recapitulated in Table 2.

### Modifier genotypes

Genotyped SNPs in the Italian cohort showed expected allele frequencies in populations of European ancestry, and Hardy–Weinberg Equilibrium (HWE) was respected except for a slight violation for *ACTN3*. Genotype distributions in the CINRG-DNHS cohort have been described,<sup>16,17,22</sup> and did not deviate from HWE (Table 3).

**Table 1.** Distribution by glucocorticoid treatment and demographics of treatment subgroups.

Treatment subgroup	<i>n</i>	Mean age in years ± SD Median age in years (min–max)
Continuously off GCs	116 (35.5%)	14.6 ± 5.9 13.7 (3.6–44.5)
Continuously on GCs	134 (41.0%)	9.4 ± 3.5 8.6 (4.2–24.8)
Started GCs during FU	9 (2.8%)	6.3 ± 1.4 6.3 (3.7–8.1)
Stopped GCs during FU	26 (8.0%)	10.5 ± 3.3 9.5 (6.9–21.6)
Multiple switches	3 (0.9%)	12 ± 4.8 10.6 (8–17.3)
Unknown	39 (11.9%)	13.0 ± 5.6 13.2 (5.5–28.0)
Total	327 (100%)	11.7 ± 5.3 10.4 (3.6–44.5)

SD, standard deviation; GCs, glucocorticoids; FU, follow-up.

**Table 2.** Distribution by DMD mutation type.

Mutation group	Italian cohort <i>n</i> (%)	CINRG-DNHS cohort <i>n</i> (%)
Deletions		
Skip 8	4 (1.5%)	5 (2.9%)
Skip 44	16 (5.8%)	16 (9.1%)
Skip 45	19 (6.9%)	22 (12.6%)
Skip 51	27 (9.9%)	36 (20.6%)
Skip 53	25 (9.1%)	12 (6.9%)
Other	101 (36.9%)	47 (26.9%)
Duplications	31 (11.3%)	12 (6.9%)
Nonsense mutations	26 (9.5%)	16 (9.1%)
Small FS mutations	13 (4.7%)	9 (5.1%)
Splice site mutations	10 (3.6%)	0 (0.0%)
Total (molecularly defined)	274 (100%)	175 (100%)

CINRG-DNHS, Cooperative International Neuromuscular Research Group Duchenne Natural History Study; “skip 8”, deletion amenable to treatment by antisense oligonucleotide promoting the skipping of exon 8; same for other exon numbers; FS, frameshifting.

### Ranges of linear decline

Using piecewise regression, we estimated in the Italian cohort that expiratory volumes decreased linearly from the age of 8.6 (FVC) or 8.5 (FEV1), to the age of 22.7 years; while PEF decreased beginning with the earliest PFTs, until the age of 27.1 (Fig. 1). In the “meta-analysis” cohort the boundaries of linear decrease were similar: 8.7–22.6 years for FVC, 8.8–19.0 for FEV1, 0–25.4 for PEF.

### Effects of age and GCs

In the Italian cohort, the GEE model estimated the rate of yearly decline ( $\pm$  standard error) of FVC as  $-4.2 \pm 0.2\%$  of predicted, while the decline of FEV1 was  $-5.0 \pm 0.3\%$ , and that of PEF was  $-2.9 \pm 0.3\%$ . GC treatment was associated with increased FVC ( $4.6 \pm 2.1\%$ ), FEV1 ( $15.5 \pm 2.0\%$ ), and PEF ( $14.2 \pm 1.9$ ). As seen in Figure 1, GC treatment was associated with higher PFT measures beginning at a younger age, but with similar decline rates over the years. Decline rates of FVC and FEV1 in the CINRG-DNHS were similar (within 0.6%), while the decline of PEF appeared somewhat faster ( $-3.8 \pm 0.2\%$ ) (Table 4).

### DMD mutation effects

In the Italian cohort, “distal” mutations downstream of exon 44 were associated with lower FVC ( $-6.1 \pm 2.3\%$ ,

**Table 3.** Allele frequencies at genotyped modifier loci.

Gene and SNP effect	SNP	Italian cohort						CINRG-DNHS cohort					
		Genotype			NA	MAF	HWE deviation	Genotype			NA	MAF	HWE deviation
		AA	AB	BB				AA	AB	BB			
<i>SPP1</i> promoter	rs28357094 (T/G)	115	62	13	137	0.23	n.s.	186	72	10	9	0.17	n.s.
<i>LTBP4</i> missense	rs10880 (C/T)	72	85	29	141	0.38	n.s.	106	129	29	13	0.35	n.s.
<i>CD40</i> 5'UTR	rs1883832 (C/T)	106	64	8	149	0.22	n.s.	150	98	19	10	0.25	n.s.
<i>ACTN3</i> nonsense	rs1815739 (C/T)	39	97	30	161	0.47	$P = 0.03$	74	114	70	19	0.49	n.s.

SNP, single nucleotide polymorphism; CINRG-DNHS, Cooperative International Neuromuscular Research Group Duchenne Natural History Study; AA, major allele homozygote; AB, heterozygote; BB, minor allele homozygote; NA, undetermined genotype (DNA unavailable or insufficient); MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium; *SPP1*, Secreted PhosphoProtein 1 (osteopontin); *CD40*, Cluster of Differentiation 40 protein, also known as *TNFRSF5* (tumor necrosis factor receptor superfamily member 5); *LTBP4*, Latent Transforming growth factor beta Binding Protein 4; *ACTN3*, actinin alpha 3.

$P = 0.008$ ), lower FEV1 ( $-6.3 \pm 2.5\%$ ,  $P = 0.011$ ), and lower PEF ( $5.8 \pm 2.3\%$ ,  $P = 0.010$ ) (Table 4). Validation in the CINRG cohort showed similar estimates with nominal significance for FVC and FEV1. With the meta-analysis approach, the detrimental effect of distal mutations showed  $P$ -values of 0.001 (FVC), 0.0094 (FEV1), and 0.013 (PEF). FVC was negatively correlated with “skip 51” and “skip 53” mutations, the latter with large effect sizes (approximately  $-10\%$ ) in all cohorts. “Skip 44” mutations showed nominally significant increases of FVC with the meta-analysis approach ( $+7.1 \pm 3.3\%$ ,  $P = 0.016$ ). “Skip 8” mutations were associated with dramatic increases of PEF ( $+20.0 \pm 4.5\%$ ) and nominally significant increases of FVC ( $+13.8 \pm 8.3\%$ ) and FEV1 ( $+15.3 \pm 7.9\%$ ). Interestingly, splice site mutations were associated with higher expiratory volumes in the Italian cohort (nominally significant; no such mutations were reported in the CINRG-DNHS). FVC and PEF trajectories were associated with different *DMD* and SNP genotypes (merged meta-analysis cohort) are shown in Figure 2.

### SNP effects


The dominant G genotype at rs28357094 in the *SPP1* promoter, associated with earlier LoA in DMD,<sup>14,22,23</sup> showed a nominally significant negative effect on FVC ( $-4.5 \pm 2.5\%$ ) in the meta-analysis. A significant effect on PEF was observed in the CINRG ( $-8.7 \pm 3.1\%$ ,  $P = 0.005$ ) and meta-analysis ( $-6.3 \pm 2.4\%$ ,  $P = 0.0088$ ) cohorts. The additive T genotype at rs1883832 in the *CD40* 5' untranslated region, also causing earlier LoA,<sup>16</sup> showed a significant negative effect on FVC in the CINRG ( $-6.1 \pm 2.2\%$ ,  $P = 0.005$ ) and meta-analysis ( $-4.8 \pm 1.7\%$ ,  $P = 0.006$ ) cohorts; and nominally significant effects on FEV1 in the CINRG-DNHS, and on PEF in the meta-analysis cohort. *LTBP4* and *ACTN3* SNPs showed no relevant associations with PFTs (Table 4).

### NIV

NIV was initiated in 87/318 participants with available data in the Italian cohort, and 31/276 in the CINRG-DNHS, at a median age of 23.2 and 22.2 years respectively (Table 5). The effect of GC treatment in delaying NIV was estimated at around 2 years in the Italian cohort ( $P = \text{n.s.}$ ), but not validated in the CINRG-DNHS. There was no clear effect of the *DMD* mutation type on NIV commencement. A nominally significant effect was observed for *SPP1*rs28357094 with the meta-analysis approach, with a hazard ratio (HR) of 1.75 (detrimental). For *CD40* rs1883832, there were nominally significant effects in the CINRG-DNHS and meta-analysis cohorts (HR 1.71 and 1.50,  $P = 0.044$  and 0.0498 respectively). Cumulative incidence plots for suggestive associations are illustrated in Figure 3.

### Discussion

Estimating yearly rates of decline of PFTs is relevant for clinical management, as it allows to gauge the relative severity of individual decline trajectories, and for the design and interpretation of clinical trials. The FVC decline slope identified in the Italian cohort ( $-4.2\%/year$ ) is in line with previous reports<sup>4,24,25</sup> which estimated values of decline around  $5\%/year$  for both FVC and PEF. The decline of PEF, on the other hand, appeared somewhat slower in the Italian cohort ( $-2.9\%/year$ ). This may be partly due to methodological aspects of our study, in which we applied linear models only within the linear age range of decline estimated by piecewise regression. PEF appeared to decline linearly over a considerably longer time, hence the smaller yearly decline. We suggest that PEF may be a more sensitive endpoint in studies involving younger boys or older adults, while FVC remains the most sensitive outcome in the approximately 10- to 20-year range.



**Figure 1.** Scatter plots of PFT measures (FVC, panels A and B; FEV1, panels C and D; PEF, panels E and F) by age, in the Italian cohort grouped by GC treatment at the time of spirometry (panels A, C, and E) and by *DMD* mutation type (“proximal” or “distal”, panels B, D, and F). Vertical lines indicate the limits of age ranges of linear decrease of corresponding measures, as identified by piecewise regression. Within these boundaries, regression lines represent the slope of decrease in the linear model (derived by regressing measure on age in the overall population and defined subgroups). PFT, pulmonary function testing; FVC, forced vital capacity.


We confirm a large effect of GCs in delaying respiratory decline in DMD. We recognize potential sources of bias which might lead to a partial overestimation of the GC effect: first, the treated population was younger, and might have benefited from an improvement of overall standards of care. Second, percent-predicted PFT values are influenced by height (denominator in the formula), and patients treated chronically with GC display stunted growth.<sup>26</sup> However, the beneficial effect of GCs appears

uncontroversial. Interestingly, treated and untreated participants show similar decline slopes (Fig. 1), but starting from a higher plateau in treated participants. This advantage is maintained over time, delaying the age at which functional thresholds related to nocturnal and diurnal respiratory insufficiency are reached. Overall, our findings support of the efficacy of GCs in preserving respiratory function in a teenage to adult age range, at doses tailored to individual tolerability.<sup>9,27</sup>

**Table 4.** Coefficients of GEE analyses.

Coefficient	Italian cohort		CINRG-DNHS cohort		Meta-analysis	
	Estimate ± SE	P-value	Estimate ± SE	P-value	Estimate ± SE	P-value
<b>FVC (% predicted)</b>						
Intercept	111.8 ± 3.9	<b>&lt;0.0001</b>	125.0 ± 4.7	<b>&lt;0.0001</b>	119.4 ± 3.0	<b>&lt;0.0001</b>
Age (per-year decrease)	-4.2 ± 0.2↓	<b>&lt;0.0001</b>	-4.8 ± 0.3↓	<b>&lt;0.0001</b>	-4.6 ± 0.2↓	<b>&lt;0.0001</b>
GC treatment	14.5 ± 2.1↑↑	<b>&lt;0.0001</b>	9.4 ± 2.3↑	<b>&lt;0.0001</b>	11.7 ± 1.6↑↑	<b>&lt;0.0001</b>
Mutation 3' of exon 44	-6.1 ± 2.3↓	<b>0.008</b>	-5.9 ± 2.7↓	0.029	-5.8 ± 1.8↓	<b>0.001</b>
<b>Mutation type</b>						
Skip 8	12.5 ± 8.9	n.s.	13.2 ± 12.0	n.s.	13.8 ± 8.3↑↑	0.049
Skip 44	6.5 ± 5.0	n.s.	7.8 ± 4.5	0.04	7.1 ± 3.3↑	0.016
Skip 45	-3.4 ± 5.2	n.s.	0.1 ± 3.3	n.s.	-0.8 ± 2.8	n.s.
Skip 51	-6.9 ± 3.8↓	0.035	-5.7 ± 3.1↓	0.031	-5.7 ± 2.3↓	<b>0.007</b>
Skip 53	-9.2 ± 3.3↓	<b>0.003</b>	-11.6 ± 4.7↓↓	<b>0.007</b>	-10.3 ± 2.7↓↓	<b>&lt;0.0001</b>
Nonsense	2.3 ± 3.2	n.s.	-6.3 ± 4.0	0.059	-1.1 ± 2.6	n.s.
Splice site	13.9 ± 7.0↑	0.023	NA	NA	13.6 ± 7.0↑	0.069
<b>SNP modifiers</b>						
rs28357094 dom	-5.3 ± 3.8	n.s.	-4.4 ± 3.2	n.s.	-4.5 ± 2.5↓	0.020
rs10880 rec	-6.8 ± 4.2	n.s.	3.4 ± 3.6	n.s.	-1.4 ± 2.8	n.s.
rs1883832 add	-0.1 ± 2.9	n.s.	-6.1 ± 2.2↓	<b>0.005</b>	-4.8 ± 1.7↓	<b>0.006</b>
rs1815739 add	4.2 ± 2.4	n.s.	0.3 ± 1.7	n.s.	0.8 ± 1.45	n.s.
<b>FEV1 (% predicted)</b>						
Intercept	125.8 ± 4.3	<b>&lt;0.0001</b>	122.6 ± 4.6	<b>&lt;0.0001</b>	127.0 ± 3.9	<b>&lt;0.0001</b>
Age (per-year decrease)	-5.0 ± 0.3↓	<b>&lt;0.0001</b>	-4.6 ± 0.3↓	<b>&lt;0.0001</b>	-5.1 ± 0.2↓	<b>&lt;0.0001</b>
GC treatment	15.1 ± 2.0↑↑	<b>&lt;0.0001</b>	8.5 ± 2.4↑	<b>0.0003</b>	13.4 ± 1.7↑↑	<b>&lt;0.0001</b>
Mutation 3' of exon 44	-6.3 ± 2.5↓	0.011	-6.6 ± 2.9↓	0.025	-5.3 ± 2.1↓	<b>0.0094</b>
<b>Mutation type</b>						
Skip 8	9.7 ± 7.5	n.s.	17.9 ± 11.4	0.058	15.3 ± 7.9↑↑	0.027
Skip 44	0.9 ± 6.0	n.s.	7.0 ± 4.5	0.059	3.2 ± 4.0	n.s.
Skip 45	-0.7 ± 5	n.s.	-2.7 ± 4.4	n.s.	-1.9 ± 3.3	n.s.
Skip 51	-7.5 ± 4.3↓	0.042	-4.8 ± 3.4	n.s.	-5.3 ± 2.9↓	0.032
Skip 53	-6.1 ± 3.8	0.053	-10.9 ± 4.7↓↓	0.010	-6.6 ± 3.2↓	0.021
Nonsense	2.7 ± 4.5	n.s.	-7.1 ± 4.3↓	0.048	-1.5 ± 3.6	n.s.
Splice site	5.8 ± 4.3	n.s.	NA	NA	11.6 ± 5.1↑↑	0.011
<b>SNP modifiers</b>						
rs28357094 dom	-3.3 ± 4.2	n.s.	-5.8 ± 3.6	0.055	-2.9 ± 2.9	n.s.
rs10880 rec	-4.3 ± 5.2	n.s.	5.4 ± 3.8	n.s.	-2.6 ± 1.9	n.s.
rs1883832 add	2.0 ± 3.1	n.s.	-4.8 ± 2.2↓	0.030	-2.1 ± 3.2	n.s.
rs1815739 add	1.3 ± 3.2	n.s.	1.2 ± 1.8	n.s.	0.6 ± 1.7	n.s.
<b>PEF (% predicted)</b>						
Intercept	89.3 ± 3.6	<b>&lt;0.0001</b>	109.4 ± 4.6	<b>&lt;0.0001</b>	90.7 ± 3.7	<b>&lt;0.0001</b>
Age (per-year decrease)	-2.9 ± 0.2↓	<b>&lt;0.0001</b>	-3.8 ± 0.2↓	<b>&lt;0.0001</b>	-3.0 ± 0.2↓	<b>&lt;0.0001</b>
GC treatment	14.2 ± 1.9↑↑	<b>&lt;0.0001</b>	8.0 ± 1.9↑	<b>&lt;0.0001</b>	14.1 ± 1.9↑↑	<b>&lt;0.0001</b>
Mutation 3' of exon 44	-5.8 ± 2.3↓	0.010	-4.7 ± 2.8	n.s.	-5.6 ± 2.3↓	0.013
<b>Mutation type</b>						
Skip 8	23.0 ± 4.2↑↑	<b>&lt;0.0001</b>	16.1 ± 6.4↑↑	<b>0.006</b>	20.0 ± 4.5↑↑	<b>&lt;0.0001</b>
Skip 44	-0.6 ± 5.4	n.s.	5.9 ± 4.2	n.s.	3.9 ± 3.5	n.s.
Skip 45	-7.8 ± 5.2	n.s.	-0.7 ± 4.4	n.s.	-2.9 ± 3.4	n.s.
Skip 51	-5.7 ± 3.4↓	0.048	-2.2 ± 3.8	n.s.	-2.9 ± 2.6	n.s.
Skip 53	-5.5 ± 2.9↓	0.027	-5.3 ± 5.2	n.s.	-5.9 ± 2.7↓	0.014
Nonsense	0.5 ± 2.8	n.s.	-6.0 ± 5.1	n.s.	-2.3 ± 3.0	n.s.
Splice site	-0.9 ± 5.1	n.s.	NA	NA	-3.0 ± 5.1	n.s.
<b>SNP modifiers</b>						
rs28357094 dom	-2.3 ± 3.5	n.s.	-8.7 ± 3.1↓	<b>0.005</b>	-6.3 ± 2.4↓	<b>0.0088</b>
rs10880 rec	-6.2 ± 4.0	n.s.	4.9 ± 4.1	n.s.	1.3 ± 3.1	n.s.
rs1883832 add	-3.7 ± 3.0	n.s.	-3.0 ± 2.2	n.s.	-4.1 ± 1.8↓	0.024
rs1815739 add	4.0 ± 2.5	n.s.	0.1 ± 1.8	n.s.	1.2 ± 1.5	n.s.

Nominally significant effects have been marked with arrows, upward for positive effects and downward for negative. Double arrows indicate "strong" effects (arbitrarily: above 10% of the corresponding measure).  $P < 0.06$  (nominally significant or close) are indicated in numbers;  $P < 0.01$  are highlighted in bold. GEE, Generalized Estimating Equation; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 sec; PEF, peak expiratory flow; CINRG-DNHS, Cooperative International Neuromuscular Research Group Duchenne Natural History Study; SE, standard error; GC, glucocorticoid corticosteroids; Skip 8, mutations amenable to treatment with skipping of exon 8 (same for other exon numbers); SNPs, single nucleotide polymorphisms; NA, not available (no participants included in the corresponding category); n.s., not significant.




**Figure 2.** Scatter plots of PFT measures (FVC, panels A, C, and E); PEF, panels (B, D, and F) by age, in the merged Italian and CINRG-DNHS cohorts grouped by *DMD* mutation type (groups defined in Methods, panels A and B) and by modifier SNP genotypes (*SPP1* rs28357094: panels C and D; *CD40* rs1883832: panels E and F). Vertical lines indicate the limits of age ranges of linear decrease of corresponding measures, as identified by piecewise regression. Within these boundaries, regression lines represent the slope of decrease in the linear model (derived by regressing measure on age in the overall population and defined subgroups). PFT, pulmonary function testing; FVC, forced vital capacity; PEF, peak expiratory flow; CINRG-DNHS, Cooperative International Neuromuscular Research Group Duchenne Natural History Study.

An unexpected finding was the lower PFT performance associated with “distal” DMD mutations, potentially affecting the expression of short dystrophin isoforms. The association in the Italian cohort was consistently validated in the CINRG-DNHS, with an effect size of around 6% for FVC and PEF. The restrictive ventilatory defect in DMD is caused by the absence of full-length dystrophin in the diaphragm and other respiratory muscles. While

defects of short dystrophin isoforms have been associated with increased risk of intellectual disability and other central nervous system (CNS) manifestations of DMD,<sup>28–30</sup> they have not been clearly linked to more severe muscle weakness. A possible explanation is that while patients with very severe cognitive deficiencies are excluded from PFTs, because of insufficient cooperation, patients with subtler CNS issues due to Dp140/Dp71 defects still





**Figure 3.** Cumulative incidence plots of NIV use by age in the merged Italian and CINRG-DNHS cohorts, grouped by (A) GC treatment (on vs. off during follow-up), (B) *SPP1* rs28357094 genotype, and (C) *CD40* rs1883832 genotype. NIV, noninvasive ventilatory assistance; CINRG-DNHS, Cooperative International Neuromuscular Research Group Duchenne Natural History Study; GC, glucocorticoid.

perform worse in PFTs, which are largely influenced by volition and effort. However, an influence of short dystrophin isoforms on other physiological variables, such as chest wall compliance or skeletal deformities, cannot be ruled out entirely, and warrants further studies.

When looking into mutations amenable to different molecular treatments,<sup>18</sup> the main anticipated finding of a milder phenotype in participants with “skip 44” deletions<sup>10–13</sup> appeared only marginal, and only nominally significant for FVC in the meta-analysis, possibly because of the relatively small size of these subgroups ( $n = 16$  in the Italian and 16 in the CINRG cohort). Even with regards to ambulatory function, it should be noted, the modifier effect of “skip 44” mutations was in fact variable.<sup>10–13</sup> Proposed underlying mechanisms involve alternative splicing of exon 44 by activation of cryptic splice sites at the deletion breakpoint,<sup>31</sup> which may vary between individuals.

Conversely, the “skip 51” and especially “skip 53” subgroups surprisingly showed worse PFT outcomes (especially PEF) across the Italian and CINRG cohorts. This finding is relevant to ongoing clinical trials of exon skipping drugs such as eteplirsen, which was recently approved in the USA,<sup>32</sup> and shown to modify slopes of FVC change compared to the genotyped CINRG cohort.<sup>33</sup> “Skip 51” and “skip 53” mutations are completely included in the “distal” group, and are predicted to disrupt Dp140 expression. Therefore, these participants may perform worse in PFTs because of the reasons explained above.

The four modifier SNPs tested here have been described because of their effect on muscle strength, mainly ambulatory function.<sup>14–17,22,23,34</sup> Respiratory involvement is more severe in DMD patients with more severe skeletal muscle impairment<sup>7</sup>; thus, modifiers of skeletal muscle strength may be considered candidate

modifiers of respiratory insufficiency. In fact, inflammatory, regenerative, and fibrotic events occur in the diaphragm as in skeletal muscle, although with potential differences,<sup>35</sup> and may be modulated by modifier genes. In this study, no loci were validated independently across the two cohorts with Bonferroni-corrected significance. Meta-analysis identified suggestive effects of *SPP1* and *CD40* on FVC and PEF, in the expected direction (minor alleles being detrimental). As previous studies on ambulatory function<sup>22</sup> and in vitro expression of osteopontin<sup>36</sup> by myogenic cells have suggested an interaction between GCs and *SPP1* via a GC receptor-mediated mechanism, a GEE model with an interaction term between rs28357094 genotype and GC treatment was also tested, but yielded no significant results (data not shown).

Both the *SPP1*-encoded cytokine osteopontin<sup>37</sup> and T-cell activation mediated by CD40<sup>38</sup> preferentially influence the earlier inflammatory phase of the dystrophic process, rather than the late, end-stage fibrotic phase.<sup>39</sup> The latter is more affected by latent transforming growth factor  $\beta$ -binding protein LTBP4,<sup>40</sup> whose disease-modifying polymorphisms did not show significant effects on PFTs. For *LTBP4*, this result did not change when taking into consideration the full VTTT/IAAM haplotype.<sup>15</sup> These findings suggest that active dystrophic pathology, that is, necrosis and inflammation within respiratory muscles, may be relevant to PFT measures, at least in the linear decline phase. The clinical meaningfulness of *SPP1* and *CD40* effects was strengthened by findings of earlier NIV associated with risk variants, although only nominally significant. These findings may in part be a consequence of prolonged ambulation, which may improve thoracic dynamics compared to wheelchair-bound patients.

We acknowledge several limitations to this study: the retrospective nature of Italian cohort data, compensated

**Table 5.** Coefficients of time-to-event analyses of age at commencement of NIV.

	Italian cohort					CINRG-DNHS cohort					Meta-analysis				
	Median age at		HR (95% CI)	P-value	n (events)	Median age at		HR (95% CI)	P-value	n (events)	Median age at		HR (95% CI)	P-value	
	n (events)	NIV (95% CI)				NIV (95% CI)	NIV (95% CI)								
All participants	318 (87)	23.2 (22.0–24.0)	NA	NA	276 (31)	22.2 (21.8–NA)	NA	NA	594 (118)	23.0 (22.0–24.0)	NA	NA	NA		
GC treatment															
Yes	166 (15)	24.0 (23.0–NA)	0.67 (0.37–1.18)	n.s.	211 (23)	22.2 (22.1–NA)	0.91 (0.41–2.06)	n.s.	377 (38)	24.0 (22.2–NA)	0.79 (0.53–1.18)	n.s.			
No	113 (62)	22.0 (20.0–24.0)			65 (8)	22.0 (21.8–NA)			178 (70)	22.4 (21.0–24.0)					
DMD mutation															
Prox.	102 (24)	23.0 (21.0–NA)	0.98 (0.59–1.60)	n.s.	58 (3)	NA (17.2–NA)	0.76 (0.21–2.71)	n.s.	160 (27)	23.2 (21.0–NA)	0.92 (0.59–1.46)	n.s.			
Dist.	168 (47)	22.9 (20.0–24.0)			117 (13)	21.8 (20.0–NA)			285 (60)	22.9 (20.0–24.0)					
SPP1 rs28357094 (dominant)															
TT	110 (20)	28.0 (25.0–NA)	1.72 (0.91–3.26)	0.094	185 (15)	25.0 (22.2–NA)	1.71 (0.80–3.66)	n.s.	295 (35)	27.0 (25.0–NA)	1.75 (1.08–2.84)	0.023			
TG/GG	72 (19)	22.9 (22.0–NA)			82 (13)	20.0 (17.4–NA)			154 (32)	22.0 (20.0–24.0)					
LTP4 rs10880 (recessive)															
CC/CT	149 (31)	24.0 (23.0–30.0)	1.27 (0.58–2.79)	n.s.	234 (29)	22.2 (21.8–NA)	0.35 (0.05–2.59)	n.s.	383 (60)	24.0 (22.2–28.0)	0.91 (0.45–1.85)	n.s.			
TT	29 (8)	23.0 19.2–NA)			29 (1)	NA (NA–NA)			58 (9)	30.9 (23.0–NA)					
CD40 rs1883832 (additive)															
CC	99 (23)	24.0 (22.0–NA)	0.97 (0.47–1.99)	n.s.	150 (11)	25.1 (22.0–NA)	1.71 (1.01–2.88)	0.044	249 (34)	24.0 (22.9–NA)	1.50 (1.00–2.26)	0.0498			
CT	63 (10)	27.0 (22.0–NA)			98 (16)	20.0 (17.0–NA)			161 (26)	23.0 (20.0–NA)					
TT	8 (0)	NA (NA–NA)			18 (3)	21.4 (16.4–NA)			26 (3)	26.0 (16.8–NA)					
ACTN3 rs1815739 (additive)															
CC	37 (7)	29.0 (19.0–NA)	1.10 (0.58–2.10)	n.s.	74 (5)	NA (20.0–NA)	0.26 (0.69–1.92)	n.s.	111 (12)	29.0 (20–NA)	1.18 (0.79–1.78)	n.s.			
CT	92 (12)	27.0 (23.2–NA)			114 (15)	22.2 (21.8–NA)			206 (27)	27.0 (23–NA)					
TT	29 (6)	22.9 (20.0–NA)			69 (7)	25.0 (22.1–NA)			98 (13)	22.9 (20.0–NA)					

Age is indicated in years. HRs above 1 indicate detrimental effects (i.e., earlier NIV), while HRs below 1 correspond to later NIV. The direction of HRs is calculated for GC treated versus untreated; "distal" versus "proximal" DMD mutation; and minor alleles for modifier SNPs (with the indicated inheritance models). CINRG-DNHS, Cooperative International Neuromuscular Research Group Duchenne Natural History Study; n (events), number of participants included in the analysis and (in brackets) number of observed events, that is, commencement of NIV; NIV, noninvasive ventilation; HR; hazard ratio; CI, confidence interval.

for by the longitudinal CINRG-DNHS<sup>4</sup>; the fact that variability in the Italian data may be affected by changes in practice during the long time frame of data collection; the unavailability of maximal inspiratory and expiratory pressure (MIP and MEP) data, which we plan to collect in future studies; the concern that missing NIV data adds uncertainty to corresponding conclusions; and finally, lack of genotyping, because of limited DNA availability, at a *THBS1* long-range genomic regulator locus recently added to the list of DMD modifiers.<sup>41</sup>

In conclusion, our findings define linear PFT changes in a large Italian DMD cohort; strengthen the indication of GC treatment for teenagers and adults living with DMD; and identify “distal” *DMD* mutations, and probably *SPP1* and *CD40* variants, as risk factors for worse PFT outcomes. These findings will ultimately be relevant for clinical management and trial design in DMD.

## Acknowledgments

We thank Mika Leinonen, MSc, from Santhera Pharmaceuticals, for providing advice regarding the statistical analyses. We acknowledge funding from Santhera Pharmaceuticals, which supported the collection and analyses of data from the Italian cohort. EP also acknowledges funding from the Cariparo Foundation (Progetto di Eccellenza “GenMod” 2017), and from Telethon Genetic BioBank (GTB12001D) and the Eurobiobank network. The CINRG-DNHS was funded by the U.S. Department of Education/NIDRR (#H133B031118, #H133B090001); U.S. Department of Defense (#W81XWH-12-1-0417); National Institutes of Health/NIAMS (#R01AR061875); Parent Project Muscular Dystrophy. We are deeply grateful to all participating patients and their families.

## Conflict of Interest

The research findings described in this article do not have direct relevance to any commercial product.

## Author Contribution

LB drafted the manuscript. LB and HGD performed statistical analyses. LB, AV, CB, EPH, CMM, and EP designed the study. GDA, MV, AF, SV, BM, DS, AB, SG, FM, GPC, MP, PT, VL, FT, ADA, EB, GA, LP, RM, GB, EA, EDM, FR, VAS, SP, SM, GLV, AB, TM, AP, MP, EM contributed to data collection and analysis, and revised the manuscript for intellectual content. All authors approved the final version of the manuscript. Cooperative International Neuromuscular Research Group (CINRG) Investigators are listed in a supplementary file.

## References

- Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. *Cell* 1987;51:919–928.
- Bello L, Hoffman EP, Pegoraro E. Dystrophinopathies. In: C. Angelini, eds. *Muscular dystrophy: causes and management*. pp. 67–96. Hauppauge, NY: Nova Science Publishers, Inc., 2013.
- Vianello A, Matarese A, Paladini L. Ventilatory assistance. In: C. Angelini, eds. *Muscular dystrophy: causes and management*. pp. 381–391. Hauppauge, NY: Nova Science Publishers, Inc., 2013.
- McDonald CM, Gordish-Dressman H, Henricson EK, et al. Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: long-term natural history with and without glucocorticoids. *Neuromuscul Disord* 2018;28:897–909.
- LoMauro A, Romei M, Gandossini S, et al. Evolution of respiratory function in Duchenne muscular dystrophy from childhood to adulthood. *Eur Respir J* 2018;51:1701418.
- Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. *Lancet Neurol* 2018;17:347–361.
- Humbertclaude V, Hamroun D, Bezzou K, et al. Motor and respiratory heterogeneity in Duchenne patients: implication for clinical trials. *Eur J Paediatr Neurol* 2012;16:149–160.
- McDonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. *Lancet* 2018;391:451–461.
- Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. *Lancet Neurol* 2018;17:251–267.
- Bello L, Morgenroth LP, Gordish-Dressman H, et al. DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study. *Neurology* 2016;87:401–409.
- Pane M, Mazzone ES, Sormani MP, et al. 6 Minute walk test in Duchenne MD patients with different mutations: 12 month changes. *PLoS One* 2014;9:e83400.
- van den Bergen JC, Ginjaar HB, Niks EH, et al. Prolonged ambulation in Duchenne patients with a mutation amenable to exon 44 skipping. *J Neuromuscul Dis* 2014;1:91–94.
- Wang RT, Barthelemy F, Martin AS, et al. DMD genotype correlations from the Duchenne Registry: endogenous exon skipping is a factor in prolonged ambulation for individuals with a defined mutation subtype. *Hum Mutat* 2018;39:1193–1202.

14. Pegoraro E, Hoffman EP, Piva L, et al. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. *Neurology* 2011;76:219–226.
15. Flanigan KM, Ceco E, Lamar K-M, et al. LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy. *Ann Neurol* 2013;73:481–488.
16. Bello L, Flanigan KM, Weiss RB, et al. Association study of exon variants in the NF- $\kappa$ B and TGF $\beta$  pathways identifies CD40 as a modifier of Duchenne muscular dystrophy [Internet]. *Am J Hum Genet* 2016;99:1163–1171. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S0002929716303834>. Accessed 31 October 2016.
17. Hogarth MW, Houweling PJ, Thomas KC, et al. Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy. *Nat Commun* 2017;8:14143.
18. Bello L, Pegoraro E. Genetic diagnosis as a tool for personalized treatment of Duchenne muscular dystrophy. *Acta Myol* 2016;35:122–127.
19. Nelson SF, Griggs RC. Predicting the severity of Duchenne muscular dystrophy: implications for treatment. *Neurology* 2011;76:208–209.
20. McDonald CM, Henricson EK, Abresch RT, et al. The Cooperative International Neuromuscular Research Group Duchenne Natural History Study—a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. *Muscle Nerve* 2013;48:32–54.
21. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. *Eur Respir J Suppl* 1993;16:5–40.
22. Bello L, Kesari A, Gordish-Dressman H, et al. Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study: ambulation in CINRG-DNHS. *Ann Neurol* 2015;77:684–696.
23. Bello L, Piva L, Barp A, et al. Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. *Neurology* 2012;79:159–162.
24. Mayer OH, Finkel RS, Rummey C, et al. Characterization of pulmonary function in Duchenne muscular dystrophy: pulmonary function in DMD. *Pediatr Pulmonol* 2015;50:487–494.
25. Ricotti V, Selby V, Ridout D, et al. Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study. *Neuromuscul Disord* 2019;29:261–268.
26. Matthews E, Brassington R, Kuntzer T, et al. Corticosteroids for the treatment of Duchenne muscular dystrophy. *Cochrane Database Syst Rev* 2016:CD003725.
27. Gloss D, Moxley RT, Ashwal S, Oskoui M. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology* 2016;86:465–472.
28. Felisari G, Martinelli Boneschi F, Bardoni A, et al. Loss of Dp140 dystrophin isoform and intellectual impairment in Duchenne dystrophy. *Neurology* 2000;55:559–564.
29. Magri F, Govoni A, D'Angelo MG, et al. Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up. *J Neurol* 2011;258:1610–1623.
30. Doorenweerd N, Mahfouz A, van Putten M, et al. Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy. *Sci Rep* 2017;7:12575.
31. Dwianingsih EK, Malueka RG, Nishida A, et al. A novel splicing silencer generated by DMD exon 45 deletion junction could explain upstream exon 44 skipping that modifies dystrophinopathy. *J Hum Genet* 2014;59:423–429.
32. Aartsma-Rus A, Krieg AM. FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the eteplirsen saga. *Nucleic Acid Ther* 2017;27:1–3.
33. Khan N, Eliopoulos H, Han L, et al. Eteplirsen treatment attenuates respiratory decline in ambulatory and non ambulatory patients with Duchenne Muscular Dystrophy. *J Neuromuscul Dis* 2019;6:213–225.
34. van den Bergen JC, Hiller M, Böhringer S, et al. Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants. *J Neurol Neurosurg Psychiatr* 2015;86:1060–1065.
35. Rouger K, Le Cunff M, Steenman M, et al. Global/temporal gene expression in diaphragm and hindlimb muscles of dystrophin-deficient (mdx) mice. *Am J Physiol Cell Physiol* 2002;283:C773–C784.
36. Vianello S, Pantic B, Fusto A, et al. SPP1 genotype and glucocorticoid treatment modify osteopontin expression in Duchenne muscular dystrophy cells. *Hum Mol Genet* 2017;26:3342–3351.
37. Pagel CN, Wasgewater Wijesinghe DK, Taghavi Esfandouni N, Mackie EJ. Osteopontin, inflammation and myogenesis: influencing regeneration, fibrosis and size of skeletal muscle. *J Cell Commun Signal* 2014;8:95–103.
38. Rosenberg AS, Puig M, Nagaraju K, et al. Immune-mediated pathology in Duchenne muscular dystrophy. *Sci Transl Med* 2015;7:299rv4.
39. Chen Y-W, Nagaraju K, Bakay M, et al. Early onset of inflammation and later involvement of TGF in Duchenne muscular dystrophy. *Neurology* 2005;65:826–834.
40. Quattrocelli M, Spencer MJ, McNally EM. Outside in: the matrix as a modifier of muscular dystrophy. *Biochim Biophys Acta Mol Cell Res* 2017;1864:572–579.

41. Weiss RB, Vieland VJ, Dunn DM, et al. Long-range genomic regulators of THBS1 and LTBP4 modify disease severity in duchenne muscular dystrophy. *Ann Neurol* 2018;84:234–245.

## Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.